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Abbreviations  
DILI: drug-induced liver injury 
ALT: alanine aminotransferase  
AST: aspartate aminotransferase 
ALP: alkaline phosphatase 
TBIL: total bilirubin 
PSTC: Predictive Safety Testing Consortium 
SAFE-T: Safer and Faster Evidence-based Translation Consortium 
IMI: Innovative Medicine Initiative 
DILIN: Drug-Induced Liver Injury Network 
AFP: alpha fetoprotein 
ARG1: arginase-1 
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CDH5: cadherin-5  
FABP1: fatty acid binding protein 1  
GSTα: glutathione S-transferase alpha 
K18: total cytokeratin 18  
ccK18: caspase cleaved cytokeratin 18  
MCSFR: macrophage colony stimulating factor receptor  
OPN: osteopontin  
GLDH: glutamate dehydrogenase  
LECT2: leucocyte cell-derived chemotaxin-2 
PON1: paraoxonase 1 normalized to prothrombin protein 
SDH: sorbitol dehydrogenase  
miR-122: microRNA-122  
ULN: upper limit of normal 
BMI: body mass index 
NMI: Natural and Medical Sciences Institute 
IQR: interquartile range 
AI: apoptotic index 
LLN: lower limit of normal 
LLoQ: lower limit of quantification 
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ROC: receiver operator characteristic 
CI: confidence interval 
CV: coefficient of variation 
AUC: area under the curve 
APAP: acetaminophen 
NSAID: non-steroidal anti-inflammatory drug 
INR: International Normalized Ratio 
MELD: Model for End stage Liver Disease  
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ABSTRACT  
Current blood biomarkers are suboptimal in detecting drug-induced liver injury (DILI) and 
predicting its outcome. We sought to characterize the natural variabilty and performance 
characteristics of fourteen promising DILI biomarker candidates. Serum or plasma from multiple 
cohorts of healthy volunteers (n=192 and =81), subjects who safely took potentially hepatotoxic 
drugs without adverse effects (n=55 and =92) and DILI patients (n=98, =28, and =143) were 
assayed for microRNA-122 (miR-122), glutamate dehydrogenase (GLDH), total keratin 18 
(K18), caspase cleaved K18 (ccK18), glutathione S-transferase alpha (GSTα), alpha fetoprotein 
(AFP), arginase-1 (ARG1), osteopontin (OPN), sorbitol dehydrogenase (SDH), fatty acid 
binding protein (FABP1), cadherin-5 (CDH5), macrophage colony stimulating factor receptor 
(MCSFR), paraoxonase 1 (PON1, normalized to prothrombin protein), and leucocyte cell-
derived chemotaxin-2 (LECT2). Most candidate biomarkers were significantly altered in DILI 
cases compared to healthy volunteers. GLDH correlated more closely with gold standard alanine 
aminotransferase (ALT) than miR-122 and there was a surprisingly wide inter- and intra-
individual variability of miR-122 levels among the healthy volunteers. Serum K18, OPN, and 
MCSFR levels were most strongly associated with liver-related death or transplant within 6 
months of DILI-onset. Prediction of prognosis among DILI patients using Model for End-stage 
Liver Disease (MELD) was improved by incorporation of K18 and MCSFR levels. Conclusion: 
GLDH appears to be more useful than miR-122 in identifying DILI patients. K18, OPN and 
MCSFR are promising candidates for prediction of prognosis during an acute DILI event. Serial 
assessment of these biomarkers in large prospective studies will help further delineate their role 
in DILI diagnosis and management. 
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Drug-induced liver injury (DILI) is a serious concern for patients, clinicians and pharmaceutical 
companies, accounting for over half of the acute liver failure cases observed in Western 
countries [1, 2]. Current detection and assessment of DILI relies on measurement of analytes that 
have been utilized for decades. Serum enzyme activities of aminotransferases, [alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST)] and alkaline phosphatase (ALP) 
are quantified as measures of hepatocellular or cholestatic injury, respectively, whilst serum total 
bilirubin (TBIL) concentration is frequently used to assess global liver function. However, 
alterations in these biomarkers are not mechanistically informative, can occur for a variety of 
reasons unrelated to hepatic injury [3-5], and can be observed with drugs that do not have the 
potential to cause clinically significant DILI [6, 7]. They also are not specific or selective for 
DILI versus other causes of liver injury. Moreover, it is not currently possible to distinguish 
benign liver chemistry elevations from those that could lead to liver failure. Hence, even mild 
aminotransferase elevations can increase liver safety concern, especially in early clinical trials. A 
combination of an injury marker (aminotransferases) and a functional marker (TBIL) in the 
absence of cholestasis and when other causes have been excluded (i.e., Hy’s Law case criteria) is 
a widely accepted prognostic model for DILI outcome [8]. However, most of the patients that 
meet Hy’s Law case criteria will not require a liver transplant or die. Ongoing efforts are 
exploring methods to improve severity prediction utilizing traditional tests [9]. Nevertheless, 
there is a clear unmet need for biomarkers that are mechanistically informative and sensitive, as 
well as specific for prediction of DILI progression or resolution.  
Substantial resources have been committed to understanding DILI and advancing candidate 
biomarkers that add value to traditional liver tests. Particularly, the Critical Path Institute’s 
Predictive Safety Testing Consortium (PSTC) in the United States and the Safer and Faster 
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Evidence based Translation (SAFE-T) consortium within the Innovative Medicines Initiative 
(IMI) in Europe were leading major efforts to validate and qualify novel DILI biomarkers [10]. 
The Drug Induced Liver Injury Network (DILIN) is a multi-center network in the United States 
created to prospectively biobank blood and tissue specimens from patients who have experienced 
DILI [11]. Each subject in this registry has undergone an unprecedented degree of phenotyping 
and most have at least six-month follow-up data aiding assessments of long-term outcomes and 
prognosis. Given the overlapping goals of these three organizations, a cross functional 
collaboration was established to study performance characteristics of candidate DILI biomarkers. 
Candidate DILI biomarkers have been identified in preliminary evaluations. However, clinical 
application of these candidate markers requires robust performance for DILI detection and 
prognosis compared to current standards. Further, it is critical that normal reference intervals be 
established for these biomarkers against which data from patients can be measured. Herein the 
results from an international collaborative effort among PSTC, SAFE-T, and DILIN are 
presented. Alpha fetoprotein (AFP), arginase 1 (ARG1), cadherin 5 (CDH5), fatty acid binding 
protein 1 (FABP1), glutathione S transferase alpha (GSTα), total keratin 18 (K18), caspase 
cleaved (cc)K18, macrophage colony stimulating factor receptor (MCSFR), osteopontin (OPN), 
glutamate dehydrogenase (GLDH), leucocyte cell-derived chemotaxin-2 (LECT2), paraoxonase 
1 (PON1, normalized to prothrombin protein), sorbitol dehydrogenase (SDH), and microRNA-
122 (miR-122) were assayed in serum or plasma from two cohorts of normal healthy subjects, 
two cohorts of patients that safely took potentially hepatotoxic drugs, and three cohorts of DILI 
patients (Table 1). DILI cohorts included patients who at 6 months had recovered completely, 
had persistent DILI or who died or required a liver transplant due to the DILI event within 6 
months of DILI-onset.  
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MATERIALS AND METHODS 
Human Subject Sample Collection 
Demographic data for the respective population cohorts can be found in Supplemental Tables 
1-3. All studies were conducted in accordance with protocols approved by local Institutional 
Review Boards and written consent was received from all participants. Inclusion and exclusion 
criteria for each cohort is described in more detail in Supplemental Methods. The primary 
causative drug implicated for all DILI patients is listed in Supplemental Table 4. Following 
isolation of serum or plasma, samples were biobanked at -80°C until analysis and may have been 
frozen for multiple years. 
Biomarker Analysis 
The 14 candidate biomarkers that were quantified in this study are listed in Table 1. Detailed 
methods for biomarker quantification can be found in Supplemental Methods. Briefly, serum or 
plasma traditional biomarker levels were quantified by clinical chemistry at the local institutions. 
Serum or plasma candidate biomarker levels were quantified in assays designed by or optimized 
by Natural and Medical Sciences Institute (NMI, Reutlingen, Germany) or at contract 
laboratories. Detailed information regarding validation parameters for all assays used in this 
study can be found in Supplemental Table 5.  
Statistical Analysis 
Descriptive statistics, median with interquartile range (IQR), were used to describe continuous 
variables, and frequency and percent were used to describe categorical variables. All statistical 
analyses were performed using JMP Genomics v8.1 or SAS software (SAS, Cary, NC) or 
GraphPad Prism 7.01 (La Jolla, CA). Biomarker distribution was visualized and the majority of 
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displayed a log normal distribution. For consistency, the absolute value of all biomarkers, with 
the exception of the Apoptotic Index (AI), were log transformed for statistical analyses. 
Statistical significance was considered p<0.05. 
Reference Interval Determination 
PSTC healthy volunteer data and SAFE-T Tel Aviv healthy volunteer data were analyzed for the 
determination of reference intervals. The reference interval lower limit of normal (LLN) and 
ULN was defined by the 5
th
 and 95
th
 percentile of the population, respectively, using a mixed 
model approach and fitted a random subject term. For two of the markers (ccK18 and GSTα) a 
substantial number of values were below the lower limit of quantification (LLoQ), so a 
maximum likelihood estimate for a truncated log-normal distribution was used to estimate the 
ULN. Because ~90% of the data for K18 was below the LLoQ, only the ULN was calculated by 
a nonparametric method. PSTC collected three serial biomarker measurements in all subjects and 
a mixed model was used to obtain the variance components for inter-and intra-individual 
variation assuming log-normal distribution. The reference interval was obtained using the 
estimated mean and standard deviation for the log-normal distribution.  
Biomarkers of DILI Detection 
Receiver operator characteristic (ROC) curve analysis was utilized to determine the performance 
of traditional and candidate biomarkers for detection of DILI patients. Biomarkers were 
considered predictive of DILI if both the ROC AUC and the lower end of the 95% confidence 
interval (CI) >0.5. All healthy volunteer and patient datasets (PSTC, SAFE-T, and DILIN) were 
used for this analysis. The relationship of liver-specific GLDH and miR-122 to ALT was 
examined. Correlation of GLDH and miR-122 with ALT was determined using Pearson’s r.   
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Biomarkers of DILI Prognosis 
Accurate outcome assessments were available only for the DILIN subjects. ROC curve analysis 
was utilized to determine which biomarkers measured in the initial DILIN sera could 
significantly predict which patients died/required a liver transplant or developed unresolved 
DILI. For a detailed description of this analysis, refer to Supplemental Methods. 
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RESULTS 
Biomarker Levels in Healthy Volunteers 
The natural variation of candidate biomakers was explored in two cohorts of healthy volunteers 
(see Supplemental Tables 1 and 2). Multiple samples returned values below the LLoQ for AFP, 
ccK18, GSTα, K18, SDH, and miR-122. The geometric mean, inter-subject variation and 
reference interval (5th and 95th percentiles) for each biomarker are presented in Table 2. Due to 
the large number of samples with K18 values that fell below the LLoQ, only the estimated 95
th
 
percentile was calculated for this biomarker. In both healthy volunteer cohorts, inter-subject 
variability of miR-122 was also high [% coefficient of variation (CV) of 90.89 and 213.51 in the 
PSTC and SAFE-T cohorts, respectively]. Further, miR-122 also showed substantial intra-
subject variability in the PSTC cohort (intrasubject %CV of 93.56) and this appeared to be most 
prominent among black individuals (Figure 1).  
The biomarker reference intervals between PSTC and SAFE-T showed substantial overlap, 
although the geometric mean tended to be slightly higher in the SAFE-T cohort. ARG1 levels, 
however, were considerably increased in the SAFE-T cohort, compared to the PSTC cohort.  
Biomarker Performance for Detecting DILI 
All candidate DILI biomarkers significantly identified patients with DILI with the exception of 
LECT2 (Table 3). The lower CI limit of LECT2 was only 0.45, indicating that the data cannot 
rule out random agreement between predictions and outcome. K18, ccK18, FABP1, and GLDH 
had AUCs > 0.9, indicating that these biomarkers are the most accurate candidate biomarkers for 
the detection of DILI. 
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GLDH levels showed a very strong correlation with ALT levels (r=0.88, p<0.0001; Figure 2A). 
miR-122 levels were also significantly correlated with levels of ALT, although the strength of 
the correlation was reduced compared to that for GLDH (r=0.66; p<0.0001; Figure 2B).   
Biomarker Alterations by Drug Class 
The SAFE-T DILI cohorts contain data from patients with acetaminophen (APAP)-related liver 
injury, as well as from patients who experienced idiosyncratic DILI related to various 
compounds (refer to Supplemental Table 4). To determine if one or more DILI 
compounds/classes produces signature biomarker changes that are unique compared to APAP-
related hepatotoxicity, SAFE-T DILI patient data were divided into broad drug classes (see 
Supplemental Methods). In general, biomarkers, including ALT, tended to be the most altered 
from other drug classes in APAP-related hepatotoxicity, emphasizing the acute and severe injury 
this compound causes (Supplemental Figure 1A). However, several biomarkers were the most 
elevated in flupirtine DILI. Specifically, TBIL (p<0.05 compared to APAP, antibiotics, chemo, 
NSAID, and other; Supplemental Figure 1B), CDH5 (p<0.05 compared to APAP, antibiotics, 
chemo, and other; Supplemental Figure 1C), and MCSFR (p<0.05 compared to APAP, 
antibiotics, chemo, NSAID, other; Supplemental Figure 1D) were significantly elevated in 
flupirtine-related liver injury. Flupirtine is an aminopyridine used as a non-opioid analgesic that 
is well recognized to cause serious DILI in Europe (not available in the US); all SAFE-T patients 
with flupirtine-related liver injury met Hy’s Law case criteria. When DILIN data were divided 
into drug categories, no significant differences were observed; however, DILIN data does not 
have patients with either APAP- or flupirtine-related hepatotoxicity (data not shown).  
Differences between cohorts in amoxicillin with clavulanic acid (Augmentin) DILI were 
explored. We found that DILIN patients with Augmentin-induced hepatotoxicity had 
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significantly elevated levels of ALT, ARG1, FABP1, GST-α, K18,  and ccK18 (p<0.05 for all) 
compared to SAFE-T DILI patients (Supplemental Table 6).  
Biomarker Performance as Prognostic Markers 
Death/Transplant 
The DILIN samples utilized in the present study were limited to those collected within 2 weeks 
of DILI onset and, per protocol, patients were tracked for at least 6 months. A small subsets of 
DILIN patients died/required a liver transplant (n=15) within 6 months and it was determined 
that the DILIN event was the cause [12]. ROC curve analysis demonstrated that traditional 
biomarkers including the international normalized ratio (INR), AST, and TBIL were predictive 
of death/liver tranplant (lower 95% CI limit >0.5; Table 4). Of the subset of candidate 
biomarkers measured in the DILIN dataset (Table 1), elevated levels of OPN, K18, MCSFR, 
ccK18, FABP1, and AFP significantly predicted death/transplant. INR was found to have the 
strongest association with death/transplant (AUC=0.920) closely followed by OPN 
(AUC=0.858). The predictive biomarkers had >2X and >7X fold changes over DILI patients that 
did not experience liver failure and healthy volunteers, respectively (Supplemental Table 7). 
The values of K18 and ccK18 measured in 98 DILIN patients enabled the calculation of an 
Apoptotic Index (AI, see Supplemental Methods for details) and AI (ccK18:K18 ratio) was also 
explored as a prognostic biomarker of death/liver tranplant (Table 4). Although both K18 and 
ccK18 levels were elevated in patients that experienced death/liver transplant, compared to 
patients that did not, the AI was significantly reduced in patients who died/required a liver 
transplant (Figure 3A-C). An AI was additionally calculated in 64 SAFE-T patients with DILI. 
Patients with flupirtine-related DILI did not have a significantly different mean AI, compared to 
patients with APAP-induced liver injury or DILI associated with other compounds (Figure 3D).  
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Current prognostic models for liver transplant and death were explored to identify whether 
incorporation of biomarkers that passed filtering criteria (OPN, K18, MCSFR, and AFP; see 
Supplemental Methods for details) could improve prediction. Model of End-stage Liver 
Disease (MELD) score ≥ 20 was highly sensitive and MELD score ≥ 30 was highly specific for 
prognosis of death/transplant in the DILIN population. Incorporating K18 and MCSFR levels 
with MELD score (when MELD values were from 20-29; Figure 4) improved the specificity of 
using MELD score ≥ 20 (specificity of 0.889 when incorporating K18 and MCSFR with MELD 
score ≥ 20 vs. 0.738 with MELD score ≥ 20 alone; Supplemental Table 8) without reducing the 
sensitivity of using MELD ≥ 20 alone (sensitivity of 0.933 for both). Hy’s Law showed moderate 
performance for prediction of death or liver transplant in this DILIN cohort (sensitivity of 0.8 
and specificity of 0.634). 
Unresolved DILI 
Nineteen patients in the DILIN cohort had unresolved DILI at their six month follow-up visit 
(persistently elevated ALT, AST, ALP, or TBIL over ULN with no competing etiology). 
Consistent with previous data, only elevated levels of ALP predicted the outcome of these 
patients (lower CI limit >0.5; Supplemental Table 9) [13]. Within this subset, 6 of the 19 
patients with unresolved DILI had ALP levels that were elevated at their six month follow-up 
visit. When data was reanalyzed to determine if candidate biomarkers could predict this subset of 
patients, it would found that GST-α (measured within two weeks of DILI-onset) was 
significantly lower in patients with prolonged ALP elevation (ROC AUC = 0.760, 95% CI = 
0.509-1.0).  
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DISCUSSION 
Traditional biomarkers of DILI may not be adequately liver-specific, offer little mechanistic 
insight into mode of injury, and are not sufficiently prognostic for injury outcome/resolution. In 
the current study, the performance of 14 candidate DILI biomarkers was explored in cohorts of 
healthy volunteers, patients who received known DILI-eliciting compounds without developing 
liver injury, and in patients who experienced DILI.  
Most of the biomarker reference intervals showed sizeable overlap between the SAFE-T and 
PSTC healthy volunteer cohorts. ARG1 levels, however, were substantially higher in the SAFE-
T compared to PSTC volunteers (Table 2). This difference could not be accounted for by 
differences in racial diversity or age. Additionally. each biomarker was quantified at the same 
facility, with the same validated assays, making technical variability an unlikely explanation to 
account for this difference. However, biomarker stability at -80° should be explored as a possible 
explanation for  ARG1 population differences, given that samples were stored from 3 months to 
3 years. The influence of race (primarily whites vs. African Americans) on biomarker reference 
ranges was explored in the PSTC cohort. Although small differences were observed (such as for 
ARG1), there was considerable overlap between biomarker ranges and unique reference intervals 
were deemed to be unnecessary in this small population.  
The biomarkers examined in this study were selected based on preliminary performance data 
generated by SAFE-T in a small pilot cohort of DILI patients and healthy volunteers (data not 
shown). Therefore, it is not surprising that most of the candidate biomarkers were significantly 
elevated in  DILI. In particular, K18, FABP1, GLDH, and ccK18 had ROC AUCs >0.90, 
suggesting that these biomarkers in particular may be useful when screening for DILI. The 
sensitivity of these biomarkers for the detection of DILI or hepatotoxicity, in general, is in 
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agreement with previously reported data [14-20]. Biomarker differences in patients with 
Augmentin-induced heptotoxicity were explored between the DILIN and SAFE-T cohorts and 
several candidate biomarkers were found to be elevated in the DILIN patients. DILIN patients 
also had higher mean elevations in serum ALT, therefore DILIN patients may in general have 
been sicker than SAFE-T patients. Indeed, while SAFE-T enrolled patients with ALT >3X ULN, 
DILIN inclusion criteria specifies that patients must have an ALT >5X ULN. 
Although very large elevations in serum ALT are generally believed to be liver-specific, ALT 
elevations are also noted following strenuous exercise and in patients with muscle diseases such 
as muscular dystrophy [3, 21]. A biomarker with greater liver-specificity could be valuable in the 
clinic when the source of an ALT elevation is uncertain. GLDH and miR-122 are highly liver-
specific and are not altered in response to muscle injury [22, 23].  GLDH is a large protein found 
within the matrix of mitochondria, enriched in the liver [24]. The inter-individual variability of 
GLDH ranged from ~53% in the PSTC cohort to ~80% in the SAFE-T cohort and intra-
individual variability was minimal (35%). In contrast, there was significant inter-individual 
variability of miR-122, a liver-specific miRNA that makes up as much as 70% of hepatic 
miRNA content [25], in both cohorts (~91 and 213% in the PSTC and SAFE-T cohorts, 
respectively) and remarkable intra-individual variability, most evident among African 
Americans, was also observed (~94%).   
MiR-122, unlike other candidate biomarkers, may not simply be leaked passively from injured 
cells, although this is believed to be the primary mechanism following injury. Instead, evidence 
suggests that miR-122 can be released actively from the liver, at least in part within extracellular 
vesicles, in response to stress [26]. For example, it has recently been shown that in response to 
stimuli and in the absence of overt hepatocyte death, miR-122 can be released and can modulate 
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activation of innate immune cells or directly regulate kidney release of erythropoetin [27, 28]. 
The variability that is inherent to miR-122 levels not only between individuals but also within 
the same individual therefore likely results from physiologic processes unrelated to damage to 
the liver. The complexity of the assay (relative to other biomarker assays), and the lack of a 
universally accepted method for data normalization, may also contribute to the variability 
observed. For these reasons, the PSTC has recently deprioritized pursuit of miR-122 as a liver-
specific biomarker, in favor of GLDH which is measured by routine clinical chemistry.  
GLDH demonstrated enhanced correlation with ALT levels and improved performance for 
detection of DILI, as compared to miR-122. Previous research explored GLDH as a biomarker of 
hepatocellular necrosis in patients with liver impairment and found it to be superior to other 
candidate biomarkers (miR-122 was not evaluated in that study) [18]. Other studies have also 
demonstrated that GLDH is elevated in patients with APAP-related toxicity [29, 30]. 
Furthermore, GLDH has been proposed as a potentially early indicator of recovery from DILI 
due to the fast elimination of GLDH observed in subjects recovering from accidental APAP 
overdose with persisting high levels of ALT [14].   
It should be noted that in spite of the large inter- and intra-individual variations in serum levels 
of miR-122 that we report here, miR-122 appears to be useful in predicting liver injury after 
APAP overdose. A recent study found that miR-122 demonstrated the highest performance for 
prediction of APAP-induced acute liver injury in a large cohort of overdose patients with normal 
ALT levels at presentation confirming results of an earlier study [14, 31]. In contrast, GLDH was 
not useful in this context. Because the method for quantitation of miR-122 in these studies 
differed from ours, it is unclear if the levels of miR-122 in patients susceptible to APAP injury 
were simply above the range of inter-and intra-individual variation meaured in the healthy 
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volunteers in our study. While the assumption is that elevated serum levels of miR-122 reflect 
early hepatocyte stress or injury due to APAP, given the increasing appreciation of the 
physiological roles of miR-122 it is possible that individuals with high baseline serum levels of 
miR-122 are more susceptible to APAP injury.  
The prognostic performance of GLDH and miR-122 was not determined in the current study 
because these biomarkers were not measured in the DILIN patient cohort (due to sample volume 
limitatinos) where outcome data was systematically collected. However, semi-quantitative 
measurements of miR-122 have previously been conducted in a subset of DILIN patients [32]. In 
contrast to the data observed in APAP-induced hepatotoxicity, reduced serum levels of miR-122 
and albumin were observed in patients that died within six months of DILI onset, compared to 
patients that recovered. Collectively, these data suggest that both miR-122 and GLDH likely 
have utility in predicting and managing DILI and factors related to extent of injury at serum 
collection time and biomarker half life may influence the interpretation of biomarker alterations. 
Research exploring the kinetics of these biomarkers in DILI may aid in interpretation of these 
biomarkers in the clinic.  
Several biomarkers showed promise as prognostic biomarkers for death/transplant in DILI. In 
particular OPN, K18, and MCSFR performed well as predictors of death/transplant. Increased 
levels of each of these biomarkers were observed in DILIN death/transplant patients compared to 
all others. OPN showed the best performance for prognosis of all candidate biomarkers in DILIN 
patients. OPN is associated with liver regeneration due to activation of hepatic stem cells [33]. 
While elevated levels of AFP, which is also released from hepatic stem cells, were prognostic for 
death/transplant, the performance of this biomarker was reduced compared to OPN (AUC= 0.687 
vs. 0.858 for AFP and OPN, respectively).  
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The increase in OPN observed in this study is in contrast to recent data demonstrating that 
patients with acute liver failure (from various etiologies) who died/received transplant had 
reduced levels of plasma OPN compared to those that recovered [34]. The difference between 
these studies may be related to the timing of sample collection. Entry into the previous study 
required acute liver failure to be occurring at enrollment (INR ≥ 1.5 and encephalopathy), 
suggesting more advanced injury than present in the current cohort.  
MCSFR, another marker of inflammation, is amongst the most promising prognostic candidate 
biomarkers (AUC=0.775) in the DILIN data for death/transplant. MCSFR, the receptor for CSF-
1, is thought to be shed from activated macrophages during DILI [35]. Interestingly, reduced 
levels of CSF-1 were associated with poor outcome in patients experiencing APAP-induced liver 
injury and this was thought to suggest that macrophages and an innate immune response are 
necessary for regeneration following liver injury [36]. The cause of this discrepancy is unclear, 
but may be related to the type of DILI examined in the current study (idiosyncratic vs intrinsic). 
MCSFR levels were considerably higher in SAFE-T patients experiencing flupirtine-induced 
hepatotoxicity compared to the 19 cases of APAP-induced hepatotoxicity, despite ALT levels 
being markedly higher in APAP-induced liver injury (Figure 2). Although no SAFE-T DILI 
patients died or required a liver transplant, all patients that experienced flupirtine-induced DILI 
met Hy’s Law case criteria, suggesting that increased MCSFR may be indicative of severe 
idiosyncratic DILI (vs. APAP-induced liver injury).  
K18 also showed value as a prognostic biomarker in DILIN patients; K18 levels were elevated in 
patients that died or needed a liver transplant, compared to patients that survived. We found that 
incorporating K18 (threshold: log normalized value of 7.98) into a model that stratified risk 
based on MELD score cutoffs of ≥ 20 and ≥ 30 improved specificity of using MELD ≥ 20, alone, 
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without decreasing sensitivity. The addition of MCSFR further improved the specificity, slightly. 
The value of K18 for prediction models of death following hepatotoxicity is in agreement with 
previously published literature [15, 37].  
K18 is an intermediate filament found in epithelial cells, including hepatocytes. Necrosis results 
in passive leakage of full length K18 into circulation while cleavage of K18 by caspases results 
in leakage of ccK18 into circulation following apoptotis [38]. Apoptosis is thought to be a more 
benign form of injury because apoptosis is not believed to result in the release of damage 
associated molecular pattens and subsequent activation of the innate immune system [39, 40]. 
Determination of the ccK18:K18 ratio, the AI, is believed to reflect the proportion of cell death 
that can be attributed to apoptosis. DILIN patients that died or needed a liver transplant had 
lower AIs than patients who recovered from DILI (i.e. consistent with necrosis as the 
predominate form of cell death in patients that died or needed a liver transplant). Because 
biopsies are not routinely conducted in the clinic, validation of the AI in humans is challenging. 
Nevertheless, pilot data in DILIN patients suggests that the AI may be useful in predicting the 
degree of apoptosis vs necrosis in liver tissue [41]. 
It should be noted that in the DILIN cohort two weeks was the maximum time between DILI-
onset (the time at which a patient’s serum liver chemistries first qualified for DILIN entry) and 
research blood collection, but the time between symptom onset (when known) and research 
blood collection varied to a larger degree, ranging from 2 to 90 days. We were unable to detect 
significant correlations between biomarker levels and days between symptom onset and research 
blood collection (r= -0.014 to 0.222; Supplemental Table 10). For example, the interval 
between symptom onset and determination of serum levels of K18 and MCSFR had Pearson r’s 
of 0.142 and 0.163, respectively. Because variation in biomarker release and clearance kinetics 
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may significantly impact interpretation of biomarker levels, future studies should include serial 
samples collected over a broad range of intervals from symptom onset. 
Resulting from the data presented here, both the Food and Drug Administration and the 
European Medicines Agency issued Letters of Support that explicitly encourage the exploratory 
use of selected biomarkers in drug registration trials and further development of K18, OPN, and 
MCSFR as potential diagnostic or prognostic DILI biomarkers [42, 43]. Further exploration of 
both miR-122 and GLDH as liver-specific alternatives to ALT was also encouraged by these 
regulatory agencies. 
In summary, the large inter- and intra-subject variation in miR-122 and the recent recognition of 
its regulated release from the liver without hepatocyte death may complicate its interpretation in 
the clinic but it is likely still valuable in certain contexts such as in the setting of APAP-induced 
hepatotoxicity. Alternatively, MCSFR may be elevated to a greater degree in severe idiosyncratic 
DILI. GLDH was a sensitive biomarker for detection of DILI and should be useful in certain 
clinical contexts to exclude muscle injury as a source of serum biomarkers [22]. K18, FABP1, 
and ccK18 were also highly sensitive for DILI detection. OPN, K18, and MCSFR show promise 
as biomarkers that can identify those DILI patients who will succumb to the DILI event unless 
transplanted. The combined use of K18, MCSFR and the MELD score improved specificity 
without reducing the sensitivity compared to use of a MELD score of  ≥20 alone.  
Based on the data reported here, follow-up initiatives should include (i) further exploration of the 
prognostic value of the biomarkers endorsed by regulatory agencies via broad application in 
clinical trials with serial sample collection (ii) correlation of the mechanism of DILI with the 
performance of the biomarkers (e.g. intrinsic DILI versus immune activation), and (iii) 
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assessment of the performance of biomarkers in drug-induced versus other causes of liver injury 
(e.g. viral hepatitis or autoimmune hepatitis). These efforts will allow the most promising 
biomarkers to be validated and qualified for routine use in clinical DILI assessment. 
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FIGURE LEGENDS 
Figure 1. Intra-Individual Variabilty in PSTC Cohort Observed in microR-122 (miR-122) 
Quantifications. Three fasting blood samples were collected from volunteers over the course of 
21 days. Greater intra-subject variability was observed in miR-122 levels amongst black subjects 
in this study compared to white subjects. Each bar represents an individual subject while circles 
represent data for miR-122 measurements 1 (white), 2 (black), and 3 (gray).  
Figure 2. Correlation Between Levels of Alanine Aminotransferase (ALT) and Liver-
Specific Biomarkers. Correlation of ALT with glutamate dehydrogenase (GLDH; A) and 
microRNA-122 (miR-122; B). Data points are individual PSTC (Predictive Safety Testing 
Consortium) and SAFE-T (Safer and Faster Evidence-based Translation) subject samples and 
represent individuals that did not have drug-induced liver injury (DILI; gray) and individuals that 
did have DILI (black). Values are log normalized. Pearson r is shown. 
Figure 3. Assessment of Keratin 18 (K18) Measurements. Differences in serum K18 (A), 
caspase cleaved K18 (ccK18; B), and Apoptotic Index (AI; C) between Drug-Induced Liver 
Injury Network patients that did not die/require a liver transplant by 6 months post-DILI-onset 
and those that did. Differences in AI (D) between SAFE-T patients experiencing DILI associated 
with flupirtine utilization and patients experiencing DILI unrelated to flupirtine. Data points 
represent individual patients. A dotted line for AI is drawn at 0.5, representing a score that 
suggests an equal contribution of apoptosis and necrosis. Values for K18 and ccK18 are log 
normalized. Significance is **p<0.01 and ***p<0.001.    
Figure 4. Incorporation of Candidate Biomarkers Into Model of End-Stage Liver Disease 
(MELD) Score Prognostic Model. Prognostic model optimized for prediction of 
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death/transplant in Drug-Induced Liver Injury (DILIN) patients (n=141) using the MELD score, 
total keratin 18 (K18), and macrophage colony stimulating factor receptor (MCSFR) 
measurements (sensitivity=0.933, specificity=0.889). White boxes represent branching points, 
light grey boxes represent patients not predicted to have an adverse outcome, and dark grey 
boxes represent patients predicted to die/require transplant. Numbers in italics represent false 
results (i.e. 18 false positives and 1 false negative).  
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Candidate 
Biomarker 
Physiological Function Tissue Localization 
Potential Utility 
in DILI 
Cohorts 
Analyzed 
AFP 
plasma protein thought to be the fetal form of 
albumin 
high levels in liver 
progenitor cells 
regeneration 
(progenitor 
cells) 
DILIN, 
PSTC, 
SAFE-T 
ARG1 
hydrolase enzyme that catalyzes the 
hydrolysis of arginine to urea and orthinine 
high levels in liver; lower 
levels in erythrocytes, 
kidney and brain 
cell injury/death 
DILIN, 
PSTC, 
SAFE-T 
CDH5 
calcium-dependent transmembrane adherens 
junction protein important for endothelial 
cell integrity and cell-cell adhesion 
broad localization 
including liver 
susceptibility 
DILIN, 
PSTC, 
SAFE-T 
FABP1 
protein involved in binding and transport of 
fatty acid 
high levels in the liver; 
lower levels in kidney and 
gastrointestinal tract 
cell injury/death 
DILIN, 
PSTC, 
SAFE-T 
GSTα 
phase II detoxification enzyme that catalyzes 
the conjugation of glutathione with various 
electrophiles 
high levels in the liver and 
multiple tissues 
cell injury/death 
DILIN, 
PSTC, 
SAFE-T 
K18 
/ccK18 
type I intermediate protein expressed in 
epithelial cells responsible for cell structure 
and integrity. Caspase cleavage results in a 
fragmented form of protein (ccK18). 
broad localization 
including liver 
cell injury/death, 
mechanism 
DILIN, 
PSTC, 
SAFE-T 
MCSFR 
 receptor on macrophages/monocytes for 
CSF, a cytokine that controls the 
proliferation, differentiation, and function of 
macrophages 
broad localization 
including liver 
inflammation 
DILIN, 
PSTC, 
SAFE-T 
OPN 
phosphoprotein involved in 
migration/infiltration of inflammatory and 
cancer cells 
broad localization 
including liver 
inflammation,  
regeneration 
(progenitor 
cells) 
DILIN, 
PSTC, 
SAFE-T 
GLDH 
mitochondrial matrix protein that catalyzes 
the conversion of 2-oxoglutarate to L-
glutamate  
high levels in the liver; 
lower levels in kidney and 
brain 
cell death, 
mechanism 
PSTC, 
SAFE-T 
LECT2 
protein involved in the recruitment of 
neutrophils 
high expression in the 
liver; lower expression in 
the testis 
regeneration 
(hepatocytes) 
PSTC, 
SAFE-T 
PON1 
HDL-associated enzyme that participates in 
paraoxonase, arylesterase, and dyazoxonase 
activites. Useful in diagnosis of NAFLD and 
NASH when normalized to prothrombin. 
produced in liver, released 
constitutively into 
circulation 
function  
PSTC, 
SAFE-T 
SDH 
enzyme involved in carbohydrate metabolism 
that converts sorbitol into fructose 
high levels in the liver, 
kidney, and testis; lower 
levels in multiple tissues 
cell injury/death 
PSTC, 
SAFE-T 
miR-122 
liver-specific  miRNA that post-
transcriptionally regulates mRNA involved 
in processes including hepatocyte 
differentiation and lipid/cholesterol 
metabolism 
high levels in the liver cell injury/death 
PSTC, 
SAFE-T 
Abbreviations: AFP, alpha fetoprotein; ARG1, arginase 1; CDH5, cadherin 5; FABP1, fatty acid binding protein 1; GST-α, 
glutathione S transferase alpha; K18, total keratin 18; ccK18, caspase cleaved K18; MCSFR, macrophage colony stimulating 
factor receptor; OPN, osteopontin; GLDH, glutamate dehydrogenase; LECT2 leukocyte cell derived chemotaxin 2; PON1, 
paroxonase 1 normalized to prothrombin protein; SDH, sorbitol dehydrogenase; miR-122, microRNA-122; HDL, high-density 
lipoprotein; NAFLD, non-alcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; DILIN, Drug-Induced Liver Injury 
Network; PSTC, Predictive Safety Testing Consortium; SAFE-T, Safer and Faster Evidence-based Translation  
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Table 2: Biomarker Reference Intervals in Healthy Volunteers 
Biomarker Unit Matrix 
PSTC (n=81) * SAFE-T (n=192) 
Est. 
Geometric 
Mean 
LLN ULN Inter-
Subj  
%CV 
Intra-
Subj  
%CV 
Est. 
Geometric 
Mean 
LLN ULN Inter-
Subj  
%CV 
Est. 5th 
Percentile 
Est. 95th 
Percentile 
Est. 5th 
Percentile 
Est. 95th 
Percentile 
AFP ng/ml serum 0.68 0.24 1.98 61.53 31.93 0.99 0.28 3.54 90.21 
ARG1 ng/ml serum 7.63 3.00 19.46 46.03 37.46 35.97 18.38 70.38 42.57 
ccK18 U/L serum 90.65 31.59 260.16 70.97 34.76 139.99 52.46 373.55 65.39 
CDH5 ng/ml serum 2798.89 1853.77 4225.87 18.00 17.69 2287.79 1222.52 4281.33 39.52 
FABP1 ng/ml serum 6.91 3.29 14.55 32.75 32.86 9.21 4.57 18.54 44.55 
GLDH U/L serum 2.71 1.01 7.24 52.74 34.53 3.00 0.95 9.51 79.68 
GSTα ng/ml serum 6.31 0.68 60.00 119.54 71.86 6.61 0.71 64.11 172.57 
LECT2 ng/ml plasma 252.27 142.07 447.96 28.64 20.97 177.96 84.74 373.74 47.50 
miR-122 copies/µl serum 2152.98 347.05 13356.52 90.89 93.56 3173.64 368.02 27367.61 213.51 
MCSFR ng/ml plasma 334.81 196.1 571.64 30.08 13.89 306.67 175.98 534.39 34.75 
OPN ng/ml serum 4.13 1.66 10.31 52.15 26.61 6.54 2.68 15.99 58.56 
PON1 ng/µg plasma 4.91 2.02 11.93 44.16 34.57 9.44 4.18 21.35 52.81 
SDH U/L serum 3.02 1.18 7.75 43.43 41.01 1.79 0.79 7.17 101.57 
K18** U/L serum 
  
121.35 
    
151.14 
 
*Three serial collections were collected for each individual. The mean value for each individual was used for all statistical analyses with the exception of intra-individual 
%CV 
**90% of K18 data was below the lower limit of quantification, therefore only an upper reference interval was determined 
Abbreviations: PSTC, Predictive Safety Testing Consortium; SAFE-T, Safer and Faster Evidence-based Translation; Est, established; LLN, lower limit of normal; ULN, 
upper limit of normal; CV, coefficient of variation; CI, confidence interval AFP, alpha fetoprotein; ARG1, arginase 1; ccK18, caspase cleaved K18; CDH5, cadherin 5; 
FABP1, fatty acid binding protein 1;  GLDH, glutamate dehydrogenase; GSTα, glutathione S transferase alpha; LECT2, leukocyte cell derived chemotaxin 2; miR-122, 
microRNA-122; MCSFR, macrophage colony stimulating factor receptor; OPN, osteopontin; PON1, paroxonase 1 normalized to prothrombin protein; SDH, sorbitol 
dehydrogenase; K18, keratin 18 
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Category Biomarker AUC 95% CI 
Traditional ALT 0.990 0.984 – 0.996 
Traditional AST 0.975 0.963 - 0.987 
Traditional ALP 0.902 0.873 -0.930 
Traditional TBIL 0.857 0.821 - 0.892 
Candidate K18 0.947 0.928 - 0.966 
Candidate FABP1 0.916 0.890 - 0.941 
Candidate ccK18 0.911 0.887 - 0.935 
Candidate GLDH 0.907 0.870 - 0.945 
Candidate MCSFR** 0.854 0.822 - 0.887 
Candidate miR-122 0.831 0.779 - 0.883 
Candidate AFP 0.826 0.793 - 0.859 
Candidate GSTα 0.827 0.792 - 0.862 
Candidate SDH 0.819 0.763- 0.876 
Candidate OPN 0.758 0.718- 0.799 
Candidate CDH5 0.658 0.614 - 0.701 
Candidate PON1 0.612 0.542 - 0.682 
Candidate ARG1 0.564 0.519 - 0.609 
Candidate LECT2 0.519 0.450- 0.588 
Abbreviations: AUC, area under the curve; CI, confidence interval; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; K18, keratin 18;  
FABP1, fatty acid binding protein 1; GLDH, glutamate dehydrogenase; ccK18, caspase cleaved K18; 
MCSFR, macrophage colony stimulating factor receptor; SDH, sorbitol dehydrogenase; miR-122, 
microRNA-122; AFP, alpha fetoprotein; GST-α, glutathione S transferase alpha; OPN, osteopontin; 
PON1, paroxonase 1; CDH5, cadherin 5; ARG1, arginase 1; LECT2, leukocyte cell derived 
chemotaxin 2; PSTC, Predictive Safety Testing Consortium; SAFE-T, Safer and Faster Evidence-
based Translation; DILI, Drug-Induced Liver Injury; DILIN, DILI Network. 
*Statistical data for all biomarkers was calculated using patient data from PSTC healthy volunteers 
(n=81), SAFE-T healthy volunteers (n=192), SAFE-T subjects that safely received DILI-eliciting 
compounds (n=147), SAFE-T DILI patients (n=126). DILIN patient data (n=143) was also used for 
all biomarkers with the exception of GLDH, miR-122, SDH, PON1, and LECT2. 
**DILIN measurements collected in serum. All other measurements collected in plasma. 
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Category Biomarker AUC 95% CI 
Value at 
Youden's 
J* 
Traditional INR 0.920 0.864-0.977 0.47 
Traditional TBIL 0.821 0.733-0.909 5.57 
Traditional AST 0.7 0.587-0.814 5.05 
Traditional ALT 0.606 0.433-0.78 6.68 
Traditional ALP 0.597 0.433-0.76 5.01 
Candidate OPN 0.858 0.759-0.957 3.38 
Candidate K18 0.832 0.737-0.927 7.98 
Candidate MCSFR 0.775 0.654-0.896 6.94 
Candidate ccK18 0.778 0.676-0.881 6.96 
Candidate FABP1 0.721 0.608-0.833 4.21 
Candidate AFP 0.687 0.566-0.809 1.57 
Candidate CDH5 0.623 0.498-0.748 8.01 
Candidate ARG1 0.588 0.436-0.741 3.47 
Candidate GST-α 0.536 0.359-0.713 6.88 
Candidate AI 0.761 0.627-0.895 0.37 
*All values with the exception of AI are log normalized. Youdin’s J is a statistic that 
estimates the probability of an informed decision. 
Abbreviations: AUC, area under the curve; CI, confidence interval; INR, international 
normalized ratio; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; ALP, alkaline phosphatase; OPN, osteopontin; K18, cytokeratin 18; 
MCSFR, macrophage colony stimulating factor receptor; ccK18, caspase cleaved K18; 
FABP1, fatty acid binding protein 1; AFP, alpha fetoprotein; ARG1, arginase 1; CDH5, 
cadherin 5; GST-α, glutathione S transferase alpha; AI, apoptotic index  
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Supplemental Figure 1: Biomarker Differences by Drug Class in Safer and Faster Evidence-
based Translation (SAFE-T) DILI Patients. Differences in mean alanine aminotransferase 
(ALT; A), total bilirubin (TBIL; B), cadherin 5 (CDH5; C), and macrophage colony stimulating 
factor receptor (MCSFR; D) between SAFE-T drug-induced liver injury (DILI) patients based on 
drug classes. Drug classes are acetaminophen (APAP; n=19), flupirtine (n=14), antibiotics (n=35), 
chemotherapeutics (n=7), non-steroidal anti-inflammatory drugs (NSAIDs; n=4), and others 
(n=45). The box in each box plot extends from the 25th percentile to the 75th percentile of data 
values; whiskers extend to minimum and maximum data with data outliers represented by circles. 
TBIL and CDH5 measurements were collected in serum while MCSFR measurements were 
collected in plasma. Significance is *p<0.05, **p<0.01, and ***p<0.001.  
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Supplemental Table 1: PSTC Demographics 
PSTC Healthy Volunteers (N=81) 
Age, y, median (IQR) 39 (29.5-50.5) 
Sex, n (%)  
Male 40 (49.4) 
Female 41 (50.6) 
Race, n (%)  
White 68 (84) 
Black 13 (16) 
BMI (kg/m2), median (IQR) 27.8 (23.7-31.35) 
Liver biochemistries, median (IQR)  
ALT (U/L) 20 (15.5-28) 
AST (U/L) 22 (19-25) 
ALP (U/L) 65 (54.5-76.5) 
TBIL (µmol/L) 8.55 (6.84-11.97) 
Abbreviations: PSTC, Predictive Safety Testing Consortium; IQR, 
interquatile range; BMI, body mass index; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; ALP, alkaline 
phosphatase; TBIL, total bilirubin 
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 Healthy Volunteers  No DILI DILI 
 Tel Aviv  Protocol 4 Protocol 5 Swiss DILI Protocol 3A 
N=192 N=55 N=92 N=28 N=98 
Age, y, median (IQR) 52 (42-62) 29 (24-39) 52.5 (43.3-61) 56 (42-66.8) 53 (38-66.3) 
Sex, n (%)      
Male 103 (53.7) 32 (58.2) 31 (33.7) 15 (53.6) 41 (41.8) 
Female 88 (45.8) 23 (41.8) 61 (66.3) 13 (46.4) 9 (47.4) 
Missing 1 (0.5)     
Race, n (%)      
White  33 (60) 68 (73.9) 25 (89.3) 90 (91.8) 
Black  20 (36.4) 11 (12) 2 (7.1) 1 (1.02) 
Asian  1 (1.8) 1 (1.1) 0 (0) 5 (5.1) 
Other  1 (1.8) 10 (10.8) 1 (3.6) 1 (5.3) 
Missing   2 (2.2)   
BMI (kg/m2), median (IQR) 25.9 (23.1- 29.2) 
21.6 (19.3-
24.8) 
25.2 (22-
29.4) 
24.6 (22-
27.4) 25.7 (23.4- 29) 
Liver biochemistries, median 
(IQR)      
ALT (U/L) 22 (18-29) 21.5 (18-35) 25 (18-32) 278 (144-1877) 
322 (137.8-
884) 
AST (U/L) 23 (20-26) 26 (20.8-33)  26.5 (22-30) 152 (64-728) 138.6 (66.5-349) 
ALP (U/L) 66 (54-81) 71 (57-9.8) 62 (46-73.5) 84.5 (65-246.8) 181 (101- 254) 
TBIL (µmol/L) 10.26 (8.6-13.7) 6.8 (5.1-10.3) 7 (5-9.8) 8.5 (5.3-32) 42 (11.5-247) 
INR    1.1 (1-1.3) 1.3 (1-1.6) 
Hy's Law, n (%)      
No    20 (71.4) 53 (54.1) 
Yes    4 (14.3) 35 (35.7) 
Missing    4 (14.3) 10 (10.2) 
Pattern of Injury, n (%)      
Cholestatic    6 (21.4) 5 (5.1) 
Mixed    1 (3.6) 24 (24.5) 
Hepatocellular    21 (75) 69 (70.4) 
R Value, median (IQR)      7.6 (1.3-75) 5.7 (2.3- 27.9) 
Abbreviations: SAFE-T, Safer and Faster Evidence-based Translation; DILI, drug-induced liver injury; IQR, 
interquartile range; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
ALP, alkaline phosphatase; TBIL, total bilirubin; INR, international normalized ratio; Hy’s Law (ALT>3X 
Upper Limit of Normal, ULN, TBIL>2X ULN, ALP<2X ULN) 
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 Recovered Unresolved Death/Transplant Unknown p N=89 N=19 N=15 N=20 
Age, y, mean ± S.D 46.2 ± 16.9 43.1 ± 16.1 52.6 ± 20.8 39.9 ± 15.9 NS 
Sex, n (%)     NS 
Male 32 (36) 10 (52.6) 9 (60) 11 (55)  
Female 57 (64) 9 (47.4) 6 (40) 9 (45)  
Race, n (%)     NS 
White 65 (73) 12 (63.2) 10 (66.7) 16 (80)  
Black 13 (14.6) 6 (31.5) 2 (13.3) 3 (15)  
Asian 5 (5.6) 0 (0) 2 (13.3) 0 (0)  
Other 6 (6.8) 1 (5.3) 1 (6.7) 1 (5)  
Ethnicity, n (%)     NS 
Hispanic 13 (14.6) 2 (10.5) 0 (0) 3 (15)  
Non-Hispanic 76 (85.4) 17 (89.5) 15 (100) 17 (85)  
BMI (kg/m2),  mean ± S.D. 28.5 ± 7.3 28.1 ± 9.6 27.4 ± 6.6 26.5 ± 5.0 NS 
Liver biochemistries, median 
(IQR)      
ALT (U/L) 527 (228.8-1258.5) 357 (128-1106) 907 (152-1536) 247 (106-458.3) NS 
AST (U/L) 306 (126.3-755.3) 290 (71-664) 865 (220-987) 
130 (63.25-
612.3) 0.01 
ALP (U/L) 165 (127.3-323.5) 216 (173- 327) 146 (120-297) 
229.5 (152.3-
356.8) NS 
TBIL (µmol/L) 93.2 (26.5-221.9) 
165.9 (73.5-
311.2) 
311.2 (261.6- 
434.3) 
177.8 (47.9-
262.5) <0.0001 
INR 1.1 (1-1.3) 1.1 (1-1.4) 3 (1.7-4.4) 1.0 (0.9-1.2) <0.0001 
Hy's Law, n (%)     0.007 
No 54 (61.4) 12 (63.2) 3 (20) 15 (75)  
Yes 34 (38.6) 7 (36.8) 12 (80) 5 (25)  
Pattern of Injury, n (%)     NS 
Cholestatic 17 (19.3) 8 (42.1) 3 (20) 10 (50)  
Mixed 16(18.2) 2 (10.5) 3 (20) 4 (20)  
Hepatocellular 55 (62.5) 9 (47.4) 9 (60) 6 (30)  
R Value, median (IQR)  8.2 (2.3-19.9) 3.8 (1- 14.7) 13.7 (3.2-36.6) 2.2 (0.9-9.3) NS 
MELD Score, median (IQR) 16.1 (103-21.7) 16.7 (12.2-19.1) 33.2 (28.9-40) 17.4 (12.9-20.2) <0.0001 
Abbreviations: DILI, drug-induced liver injury; BMI, body mass index; IQR, interquartile range; ALT, alanine 
aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TBIL, total bilirubin; INR, international 
normalized ratio; Hy’s Law (ALT>3X Upper Limit of Normal, ULN, TBIL>2X ULN, ALP<2X ULN); MELD, Model of 
End-stage Liver Disease 
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Primary Causative Drug  Patients  (n) Drug Class SAFE-T DILIN 
Acetaminophen 19   APAP 
Acetaminophen and Others 3   APAP + Others 
Acetazolamide 1   Others 
Allopurinol   1 Others 
Althiazide 1   Others 
Amino Acids Nos   1 Others 
Amiodarone   1 Others 
Amoxicillin 1 1 Antibiotics 
Amoxicillin W/Clavulanic Acid 9 11 Antibiotics 
Amphetamines 1   Others 
Anabolic Agents For Systemic Use 3 4 Others 
Anakinra   1 Others 
Antiinflammatory And Antirheumatic Products,   1 Others 
Antithymocyte Immunoglobulin   1 Others 
Asparaginase   1 Chemotherapy 
Atorvastatin 5   Others 
Azathioprine 1 1 Others 
Azithromycin 2 3 Antibiotics 
Baclofen 1   Others 
Beta-Interferon 2   Others 
Bortezomib 1   Others 
Bupropion   1 Others 
Camellia Sinensis   1 Others 
Carbamazepine 1 2 Others 
Carbohydrates/Proteins/Minerals/Vitamins, Com   1 Others 
Cefalexin   1 Antibiotics 
Cefazolin   2 Antibiotics 
Cefotaxime   1 Antibiotics 
Ceftriaxone 2 1 Antibiotics 
Celecoxib 1   NSAID 
Centrally Acting Sympathomimetics   1 Others 
Ciprofloxacin   4 Antibiotics 
Clarithromycin   1 Antibiotics 
Cyclophosphamide 1   Chemotherapy 
Cyclosporine A 1   Others 
Dantrolene   1 Others 
Dapsone   1 Antibiotics 
Daptomycin   1 Antibiotics 
Darunavir   2 Others 
Diclofenac   2 NSAID 
Disulfiram 1 1 Others 
Doxepin 1   Others 
Doxycycline 1 1 Antibiotics 
Erythromycin W/Sulfisoxazole   1 Antibiotics 
Escitalopram   2 Others 
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Etoricoxib 1   NSAID 
Exemestane 1 1 Others 
Fenofibrate 1 2 Others 
Fingolimod 1   Others 
Flavocoxid   1 Others 
Flucloxacillin 6   Antibiotics 
Flupirtine 14   Flupirtine 
Fluvastatin 1   Others 
Gabapentin 1   Others 
Herbals   7 Others 
Hydralazine   2 Others 
Hydroxycut - Ephedra Free   2 Others 
Ibuprofen 2   NSAID 
Imetelstat   1 Chemotherapy 
Infliximab   2 Others 
Ipilimumab   1 Chemotherapy 
Isoniazid   12 Anti-TB 
Isoniazid/pyrazinamide/rifampin 1   Anti-TB 
Isoniazid/pyrazinamide/rifampin/ ethambutol 1   Anti-TB 
Leflunomide 2   Others 
Letrozole 1   Others 
Levofloxacin 1 3 Antibiotics 
Lisinopril   1 Others 
Metamizole 3   Others 
Mercaptopurine   2 Chemotherapy 
Meropenem 1   Antibiotics 
Methyldopa 1 2 Others 
Micafungin   1 Others 
Minocycline   5 Antibiotics 
Montelukast   1 Others 
Moxifloxacin   1 Antibiotics 
Mushrooms 1   Others 
Nefazodone   1 Others 
Nicotinic Acid   3 Others 
Nitrofurantoin 1 2 Antibiotics 
Octreotide   1 Others 
Olanzapine 1   Others 
Oxaliplatin   2 Chemotherapy 
Oxymethalone 1   Others 
Pantaprazole 1   Others 
Pentamidine 1   Others 
Pegaspargase   2 Chemotherapy 
Phenprocoumon 1   Others 
Phenylpropanolamine   1 Others 
Phenytoin   3 Others 
Piperacillin Sodium W/Tazobactam 2 1 Antibiotics 
Pravastatin   1 Others 
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Prednisolone 1   Others 
Pregabalin 1 1 Others 
Propylthiouracil   2 Others 
Quetiapine   2 Others 
Rifampin 1   Anti-TB 
Several Antibiotics 5   Antibiotics 
Several Chemoterapeutics 5   Chemotherapy 
Simvastatin 1 1 Others 
Sulfamethoxazole W/Trimethoprim 1 11 Antibiotics 
Sulfasalazine   1 Others 
Tacrolimus 1   Others 
Temozolomide 1   Chemotherapy 
Terbinafine 1   Others 
Thiamazole 1   Others 
Valaciclovir   1 Others 
Valproic Acid   1 Others 
Other   3 Others 
Query Outstanding   1   
Abbreviations: SAFE-T, Safer and Faster Evidence-based Translation; DILIN. Drug-Induced Liver Injury Network; 
APAP, acetaminopen 
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Supplemental Table 5: Biomarker Validation Data 
Analyte  Type of Assay 
Sample 
Matrix 
analyzed 
unit LOD LLoQ   ULoQ  
intra-
assay 
precision 
(% CV) 
inter-
assay 
precision 
(% CV) 
dilutional 
linearity of 
high conc 
sample 
Spike-in 
recovery 
(%) 
short 
term 
stability 
(24h at 
RT and 
4°C) 
F/T 
stability, 3 
cycles 
ccK18 ELISA Serum U/L 16.2 62.5 1000 2.2 5.7 - 7.9 up to 1:16 112 - 118 yes yes 
K18 ELISA Serum U/L 20 100 5000 3.7 6.1 - 9.4 up to 1:32 83 - 107 yes yes 
GLDH Activity Assay Serum U/L 0.3 1 80 0.4 - 7.7 1.5 - 6.4 1:4 - 1:256 ND 
yes, > 
6h yes 
GSTα Immunoassay Serum ng/mL 1.79 1.82 373  1 - 14 11-Sep 1:5 - 1:10 77 - 94 yes yes 
AFP Immunoassay Serum ng/mL 0.367 0.367 584 16-Feb 13-Jul 1:5 - 1:40 99 - 106 yes yes 
ARG1 Immunoassay Serum ng/mL 1.6 7.4 800 6.4 - 11.9 4.3 - 15.7 1:4 - 1:256 84 - 88 yes yes 
OPN Immunoassay Serum ng/mL 1.25 1.25 1149 5-Jan  6 -  11 1:5 - 1:10 81 - 85 yes yes 
SDH Activity Assay Serum U/L 0.3 0.5 50 0.6 - 10.6 1.7 - 13.4 up to 1:32 ND 
yes, > 
6h yes 
miR-122 RT-qPCR Serum copies/µL ND 384 5089837 1.3 - 12.1 0.5 - 25.4 ND ND 2h RT, 5h 4°C yes 
FABP1 Immunoassay Serum pg/mL 3.1 15.6 16000 5.6 6.7 - 18.1 1:2 - 1:2048 
110 - 
115 yes yes 
CDH5 ELISA Serum ng/mL 0.36 3.13 100 6 4.7 - 7.2 1:40 - 1:640 50 - 83 yes yes 
MCSFR Immunoassay EDTA-Plasma pg/mL 170 600 10000 1.1 - 13.9 8.0 - 28.0 up to 1:3,200 71 -79 yes yes 
PON1 Immunoassay EDTA Plasma ng/mL 0.06 0.35 600 5.9 8.3 - 12.3 1:20 - 1:160 64 - 82 
4h RT, 
24h 4°C yes 
Prothrombin Immunoassay EDTA Plasma µg/mL 0.8 1.92 200 4.7 1.7 - 4.5 1:40 - 1:320 79 - 108 yes yes 
LECT2 Immunoassay EDTA Plasma ng/mL 2 5.56 300 7.8 11.7 - 12.6 
1:40 - 
1:1.280 94 - 118 yes yes 
Abbreviations: limit of detection (LOD) , lower limit of quantification (LLoQ),upper limit of quantification (ULoQ), coefficiant of variability (CV), concentration (conc), 
hours (h), room termperature (RT), freeze/thaw (F/T),  total cytokeratin 18 (K18), caspase cleaved cytokeratin 18 (ccK18), glutamate dehydrogenase (GLDH),  not 
determined (ND), glutathione-S-transferase α (GSTα), alpha fetoprotein (AFP), arginase 1 (ARG1), osteopontin (OPN), sorbitol dehydrogenase (SDH), microRNA-122 
(miR-122), reverse transcription quantitative real-time PCR (RT-qPCR),  liver fatty acid binding protein (L-FABP), cadherin 5 (CDH5), macrophage colony stimulating 
factor receptor (M-CSF-R), paroxonase 1 (PON1, normalized to prothrombin protein), leukocyte cell-derived chemotaxin 2 (LECT2) 
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Biomarker Mean Biomarker Value (Ln) p SAFE-T DILIN 
ALT (U/L) 4.67 5.46 0.048 
ARG1 
(ng/ml) 2.83 3.52 0.033 
FABP1 
(ng/ml) 2.82 3.82 0.04 
ccK18 (U/L) 5.75 6.29 0.028 
Abbreviations: DILI, drug-induced liver injury; SAFE-T, safer and faster 
evidence-based translation; DILIN, DILI network; ARG1, arginase 1; FABP1, 
fatty acid binding protein 1; ccK18, caspase cleaved keratin 18 
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Biomarker 
Geometric Mean Fold Change 
HV No Death/Trans Death/Trans HV vs. Death/Trans 
No Death/Trans 
vs. Death/Trans 
OPN (ng/ml) 5.75 14.17 41.01 7.13 2.89 
K18 (U/L) 68.44 1358.73 10481.29 153.15 7.71 
MCSFR (ng/ml) 315.4 883.93 2240.95 7.11 2.54 
ccK18 (U/L) 121.83 978.14 3636.49 29.85 3.72 
FABP1 (ng/ml) 8.54 50.14 133.7 15.66 2.67 
AFP (ng/ml) 0.9 4.47 10.32 11.47 2.31 
Abbreviations: DILIN, drug-induced liver injury network; HV, healthy volunteer; trans, transplant; OPN, 
osteopontin; K18, total keratin 18; MCSFR, macrophage colony stimulating factor receptor; ccK18, caspase 
cleaved keratin 18; FABP1, fatty acid binding protein 1; AFP, alpha fetoprotein 
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Hy's Law  0.8 0.634 0.207 0.964 0.0054 
MELD score ≥ 20 0.933 0.738 0.298 0.989 <0.0001 
MELD score ≥ 30 0.6 0.992 0.9 0.954 <0.0001 
Modified Hy's Law* 0.733 0.611 0.183 0.951 0.0303 
ALF Algorithm* 0.533 0.817 0.258 0.936 0.0075 
MELD + K18/MCSFR 0.933 0.889 0.5 0.991 <0.0001 
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; Hy’s Law (ALT>3X 
Upper Limit of Normal, ULN, TBIL>2X ULN, ALP<2X ULN); MELD, Model of End-stage Liver 
Disease; ALF, acute liver failure; K18, total keratin 18; MCSFR, macrophage colony stimulating 
factor receptor. 
*Robles-Diaz M, Lucena MI, Kaplowitz N, Stephens C, Medina-Caliz I, Gonzalez-Jimenez A, et al. 
Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-
induced liver injury. Gastroenterology 2014;147:109-118 e5. 
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Category Biomarker AUC 95% CI 
Traditional ALP 0.67 0.562-0.777 
Traditional TBIL 0.629 0.497-0.761 
Traditional ALT 0.544 0.39-0.7 
Traditional INR 0.528 0.376-0.679 
Traditional AST 0.516 0.369-0.664 
Candidate GST-α 0.633 0.485-0.78 
Candidate ARG1 0.614 0.48-0.747 
Candidate ccK18 0.58 0.442-0.719 
Candidate OPN 0.562 0.436-0.688 
Candidate FABP1 0.562 0.418-0.706 
Candidate CDH5 0.539 0.406-0.673 
Candidate AFP 0.538 0.397-0.679 
Candidate K18 0.519 0.374-0.664 
Candidate MCSFR 0.516 0.385-0.647 
Candidate AI 0.53 0.359-0.702 
*All values with the exception of AI are log normalized 
Abbreviations: AUC, area under the curve; CI, confidence interval; INR, international normalized ratio; TBIL, total bilirubin; 
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; OPN, osteopontin; K18, 
cytokeratin 18; MCSFR, macrophage colony stimulating factor receptor; ccK18, caspase cleaved K18; FABP1, fatty acid 
binding protein 1; AFP, alpha fetoprotein; ARG1, arginase 1; CDH5, cadherin 5; GST-α, glutathione S transferase alpha; AI, 
apoptotic index  
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Biospecimen Collection in DILIN Patients 
Biomarker Pearson's r 
AFP 0.077 
ARG1 -0.014 
CDH5 0.222 
K18 0.142 
ccK18 0.212 
FABP1 -0.002 
GST-α -0.048 
MCSFR 0.163 
OPN 0.158 
Abbreviations: DILIN, drug-induced liver injury network AFP, 
alpha fetoprotein; ARG1, arginase 1; CDH5, cadherin 5; K18, 
cytokeratin 18; ccK18, caspase cleaved K18  FABP1, fatty acid 
binding protein 1; GST-α, glutathione S transferase alpha;  
MCSFR, macrophage colony stimulating factor receptor; OPN, 
osteopontin;  
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PSTC Healthy Volunteers 
All subjects in this cohort (n=81; Supplemental Table 1) were recruited at the Jasper Clinic, Inc., 
Kalamazoo, MI, USA. Three fasting blood samples (n=243 total samples) were collected from 81 
subjects over 21 days. Inclusion criteria included age between 18 and 70 years, no underlying 
medical conditions or use of chronic medications, and a body mass index (BMI) < 35 (kg/m2) (two 
exceptions with BMIs of 35.3 and 37.6 kg/m2). Exclusion criteria included a positive test for 
human immunodeficiency virus, and/or active hepatitis B or hepatitis C viral infections, a medical 
intervention performed within three months of study enrollment, a positive pregnancy test, or 
unwillingness to refrain from illicit drug/alcohol/tobacco use or strenuous exercise during the 
study.  
SAFE-T Healthy Volunteers 
Biomarker measurements from subjects in this cohort (n=192; Supplemental Table 2) were taken 
from a single fasting blood sample collected between 7 and 9 a.m. at the Tel Aviv Sourasky 
Medical Center, Tel Aviv Israel. All subjects were asymptomatic and in good health. They 
completed a detailed epidemiological questionnaire and underwent a thorough analysis of life style 
by a trained nutritionist. Subjects were interviewed regarding their personal and family history and 
underwent a comprehensive physical examination. Female subjects underwent a breast and pelvic 
exam by a senior surgeon and mammography was performed at age > 40 years. Heavy smokers 
(>20 packs/year) were offered a computed tomography scan. Men > 40 years were tested for total 
and free prostate-specific antigen. Further diagnostic tests were performed as needed based on the 
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diseases, and a personal or family history of cancer.   
SAFE-T DILI Patients 
The clinical studies analyzed in this manuscript can be divided into (i) protocols that recruited 
patients diagnosed with DILI (Supplemental Table 2, “DILI”) and (ii) protocols that recruited 
patients who safely took a known DILI-eliciting compound and who were prospectively monitored 
for several months without evidence of liver injury (Supplemental Table 2, “No DILI”). Fasting 
blood samples were collected. The SAFE-T criteria for adjudicating suspected DILI cases have 
been described elsewhere [1]. With few exceptions, DILI patients fulfilled the consensus criteria 
for DILI as previously published [2, 3]. 
SAFE-T DILI Patients: 
Swiss DILI study: This study was an 8-week single-center follow-up study investigating the 
prognostic value of new biomarkers in patients with DILI and included 28 patients adjudicated as 
having DILI. None of the patients included from this protocol died/required a liver transplant 
during the observation period. It is unknown whether these patients developed chronic DILI. 
Protocol 3A: This study was a 12-week multi-center follow-up study investigating the prognostic 
value of new biomarkers in patients with DILI and included 98 patients adjudicated as DILI. None 
of the patients included from this protocol died/required a liver transplant during the observation 
period. It is unknown whether these patients developed chronic DILI. 
SAFE-T Drug-exposed No DILI Patients: 
Protocol 4: This study was a 9-month single-center follow-up study in tuberculosis patients (n=55) 
starting anti-tuberculosis drug therapy. None of the patients enrolled in this protocol developed 
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measurements were made in samples collected at a time point after the patients had begun taking 
compound (time ranged from 1-6 months on compound). 
Protocol 5: This study was a 3-year single-center follow-up study in rheumatoid arthritis patients 
and 92 patients were included in this analysis. None of the patients enrolled in this protocol 
developed DILI (ALT >5X ULN) during the observation period. When possible biomarker 
measurements were made in samples collected at time points after patients had begun taking 
compound (time ranged from 6-30 months on compound); however, only a baseline sample was 
available for some of these individuals (n=26). 
DILIN Patients 
DILIN prospectively collects clinical, laboratory, imaging, and histopathological information as 
well as biospecimens from patients within 6 months of suspected DILI onset at multiple centers 
across the United States (Supplemental Table 3). The criteria utilized for DILI assessment in this 
network has been described in detail elsewhere [4]. The current study assessed biomarkers in 143 
samples and included only patients with probable, highly likely, or definite DILI and a blood 
sample collected within two weeks of DILI onset. Within this cohort, 15 patients died/required a 
liver transplant within 6 months of onset because of their DILI. Following a readjudication process, 
DILI was deemed to be the primary factor in all of these patients [5]. Additionally, 19 patients had 
unresolved DILI (persistently elevated ALT, AST, ALP, or TBIL in the absence of a competing 
etiology) at 6 months following onset. Of the remaining patients, 89 had recovered by their 6 
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their liver injury had completely resolved. 
Biomarker Quantification 
Predictive Safety Testing Consortium (PSTC) and Safer and Faster Evidence-based Translation 
(SAFE-T) biomarker measurements were made in either serum or EDTA-plasma (plasma) 
depending on which matrix was determined to be better suited for the assay. Leucocyte cell derived 
chemotaxin 2 (LECT2), macrophage colony stimulating factor receptor (MCSFR), and 
paraoxonase 1 (PON1; normalized to prothrombin protein) were quantified in plasma. All other 
biomarkers were quantified in serum. All Drug-Induced Liver Injury Network (DILIN) biomarker 
measurements were made in serum samples. Of the subset of biomarkers measured in all datasets 
(due to limitations on sample volume, only 9/14 biomarkers were examined in DILIN patients), 
the matrix for MCSFR differed between cohorts because of sample availability. For all analytes, 
no international reference standard was available and the measured concentrations were calculated 
based on individual standard proteins used for the assay calibration.  
Traditional biomarkers alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
alkaline phosphatase (ALP), total bilirubin (TBIL), and international normalized ratio (INR) were 
measured at the local institutional clinical laboratories and were not obtained from stored samples. 
Samples utilized for candidate biomarker analyses were taken from archived samples stored at ≤ -
70°C. Measurements were made at Natural and Medical Sciences Institute (NMI; Reutlingen, 
Germany) or at contract research laboratories. Briefly, ELISA assays were used to measure total 
keratin 18 (K18), caspase cleaved K18 (ccK18; VLVbio, Stockholm, Sweden) and cadherin 5 
(CDH5; R&D Systems, Minneapolis, MN). Sandwich immunoassays were used to measure 
glutathione S transferase alpha (GSTα), alpha fetoprotein (AFP), osteopontin (OPN; optimized 
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prothrombin protein, fatty acid binding protein 1 (FABP1), and LECT2 (assays developed by NMI, 
Germany). Colorimetric applications for glutamate dehydrogenase (GLDH) activity (Roche 
Diagnostics, Grenzach-Wyhlen, Germany) and sorbitol dehydrogenase (SDH) activity (Sekisui 
Diagnostics, Lexington, MA, USA) were run on a Roche P. Modular Analyzer. PON1 was 
normalized to prothrombin protein because evidence suggests that this normalization method 
enables distinction from nonacloholic steatohepatitis and nonalcoholic fatty liver disease [6]. 
Absolute quantification of microRNA-122 (miR-122) was analyzed by reverse transcription 
quantitative real time PCR utilizing standard reagents and real time hydrolysis probes (Life 
Technologies, Grand Island, New York). Differences in RNA extraction efficiency from individual 
serum samples were compensated for by adding a synthetic non-human miR (mmu-miR-293) to 
all samples prior to extraction. All PCR analyses were performed on 192.24 Dynamic Array IFC 
(Fluidigm). Cq values were calculated by averaging the technical triplicate Cq values, normalized 
by the average Cq value of the spiked mmu-miR-293 and total miR-122 copy numbers/µL were 
calculated.   
When a biomarker value fell below the lower limit of quantification (LLoQ), that value was used 
as LLoQ/2. 
All commercial assay kits were run according to manufacturer’s recommended protocols. All non-
clinical assays used for analysis of sample sets which were performed at NMI or contract research 
organizations were validated following a fit-for-purpose approach considering usual guidelines. 
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the assays were released for sample screenings.  
When permissable, an apoptotic index of injury (AI) was calculated from patient data utilizing the 
ratio of ccK18 to K18. Evidence has demonstrated that this ratio is only meaningful when ccK18 
and K18 are above background threshhold levels [7]. In the current study, the following rules were 
set to establish when calculation of an AI was appropriate: a) K18 ≥ 500 U/L b) ccK18 ≥ 200 U/L 
c) K18 > ccK18. Using these rules, an AI was calculated for 98 DILIN patients and 64 SAFE-T 
DILI patients. Significance was determined by logistic regression and was considered p<0.05. 
Biomarker Differences by Drug Class  
To determine if one or more DILI compounds/classes produces signature biomarker changes that 
are unique compared to APAP-related DILI, SAFE-T DILI patient data were divided into broad 
drug classes. Data was divided as follows: APAP (n=19), flupirtine (n=14), antibiotics (n=35), 
chemotherapeutics (n=7), non-steroidal anti-inflammatory drugs (NSAIDs; n=4), and others 
(n=45). When a primary causative drug was uncertain, data were excluded (n=2). Biomarker 
differences in drug classes were determined in SAFE-T DILI data and DILIN patient data utilizing 
a one way ANOVA and Wilcoxon multiple comparison correction.  
Additionally, cohort differences in patients with DILI related to amoxicillin with clavulanic acid 
(Augmentin) was examined between DILIN (n=11) and SAFE-T (n=9). Differences were 
determined using a Wilcoxon test. 
Prognostic Model Generation 
The performance of current DILI outcome prediction models including Hy’s Law, Model for End 
Stage Liver Disease (MELD) ≥ 20, MELD ≥ 30, along with a modified version of Hy’s Law and 
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current DILIN patient cohort. Patients were assigned a binary label based on whether or not they 
met model criteria. Hy’s Law criteria was met if patients had ALT ≥ 3X upper limit of normal 
(ULN), TBIL ≥ 2X ULN, and ALP < 2X ULN. A MELD score for each patient was calculated as 
previously described [9]. Concurrent sodium levels were not utilized in this calculation. 
Performance characteristics (sensitivity, specificity, positive predictive value, PPV, and negative 
predictive value, NPV) were determined and a contingency table and Fisher’s exact test were used 
to establish significance.  
We were interested in determining if candidate DILI biomarkers added value to predictions of 
death/transplant made with traditional biomarkers. The statistical literature and related data 
suggest that at least 10 cases are needed for every covariate in a logistic regression prediction 
model to avoid over-fitting; otherwise, the parameter estimators will be unstable, the covariates in 
the model may represent noise instead of the true effects of underlying risk factors, and precision 
of parameter estimators will be poor [10]. Because only n=15 patients in this cohort required a 
liver transplant or died as a result of DILI, construction of a predictive model using only the 
biomarker data from this study was not attempted. Instead, we sought to determine if incorporation 
of any candidate biomarkers could improve the performance of common or previously described 
predictive models (that use traditional biomarker data). To reduce the number of candidate 
biomarkers being examined in this analysis, only biomarkers considered predictive of outcome 
(AUC and lower tail of 95% CI both > 0.5) were carried forward. Predictive biomarkers were then 
used to construct a correlation matrix and Pearson’s r for each biomarker combination was 
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greatest AUC generated in ROC curve analysis was carried forward.   
Novel biomarkers were also incorporated into a model that utilized MELD score, given that MELD 
≥ 20 was the most sensitive prediction model and MELD ≥ 30 was the most specific prediction 
model. Because most of the  ”false” tests when using MELD score were observed when a patient’s 
MELD score was between 20 and 30, we determined if adding novel biomarker quantifications to 
this subset of patients would improve the MELD performance. Any patient with a MELD score 
<20 was considered ”recovered.” And patient with a MELD score ≥30 was considered ”adverse.” 
Using the biomarkers that passed our earlier filters (K18, OPN, MCSFR, and AFP) we first 
determined the single biomarker that best impoved the specifity of the MELD score model (one 
”adverse” patient had a MELD score <20, therefore the sensitivity of the model could not be further 
improved using this approach) without negatively affecting the sensitivity. Once this biomarker 
was identified, we determined if adding a second biomarker could improve the specificity further. 
This analysis was performed using data from 141 DILIN patients (2 patient had missing laboratory 
values). Youden’s J is a single statistic that estimates the probability of an informed decesion and 
captures the performance of a binary test. Therefore, The value corresponding to the best 
Younden’s J for each biomarker was used as an unbiased cut-off threshold for calling the outcome 
of each patient. Receiver operating characteristic (ROC) curve performance characteristics were 
examined when each biomarker was added alone or when a combination of the candidate 
biomarkers was incorporated. The combination of biomarkers that gave the best performance (K18 
and MCSFR) was reported.  
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